Diabetic nephropathy

被引:0
|
作者
Menne, J. [1 ]
Haller, H. [1 ]
机构
[1] Hannover Med Sch, D-30625 Hannover, Germany
来源
INTERNIST | 2011年 / 52卷 / 05期
关键词
Albuminuria; Hypertension; HbA(1c); Renin angiotensin system; Diabetic nephropathy; STRUCTURAL-FUNCTIONAL RELATIONSHIPS; CARDIOVASCULAR EVENTS; RENAL-DISEASE; MICROALBUMINURIA; INTERVENTION; METAANALYSIS; ALBUMINURIA; PROTEINURIA; PREVENTION; MORTALITY;
D O I
10.1007/s00108-010-2761-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic nephropathy is the most common cause of end-stage renal disease. Since the disease progresses very slowly and usually takes more than 20 years before terminal renal failure occurs, early intervention is of great importance in order to prevent this disabling complication. A good control of diabetes with HbA(1c) levels around 7% is desirable. At least as important is the treatment of elevated blood pressure values. The target value for patients with diabetes has been adjusted in the last year and is now 130-139/80-85 mmHg. Should (micro-)albuminuria or renal insufficiency be present the blood pressure target is < 130/80 mmHg. For the control of hypertension the use of ACE inhibitors or angiotensin receptor blockers is recommended. In addition, the control of other risk factors and appropriate therapeutic intervention is required. A multifactorial intervention leads to the best results and can avoid the occurrence or progression of diabetic kidney disease and other micro- and/or macrovascular complications.
引用
收藏
页码:495 / +
页数:8
相关论文
共 50 条
  • [1] Clinical impact of albuminuria in diabetic nephropathy
    Wada, Takashi
    Shimizu, Miho
    Toyama, Tadashi
    Hara, Akinori
    Kaneko, Shuichi
    Furuichi, Kengo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (01) : 96 - 101
  • [2] Novel therapies of diabetic nephropathy
    Burney, Basil O.
    Kalaitzidis, Rigas G.
    Bakris, George L.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (02) : 107 - 111
  • [3] Identification of the Stages of Diabetic Nephropathy at Which Angiotensin II Receptor Blockers Most Effectively Suppress Albuminuria
    Ogawa, Susumu
    Matsushima, Masato
    Mori, Takefumi
    Okamura, Masashi
    Senda, Miho
    Sakamoto, Takuya
    Nako, Kazuhiro
    Ito, Sadayoshi
    AMERICAN JOURNAL OF HYPERTENSION, 2013, 26 (09) : 1064 - 1069
  • [4] The role of ramipril in the therapy of diabetic nephropathy
    Dezsi Csaba Andras
    ORVOSI HETILAP, 2014, 155 (07) : 263 - 269
  • [5] Up-Date on Diabetic Nephropathy
    Pelle, Maria Chiara
    Provenzano, Michele
    Busutti, Marco
    Porcu, Clara Valentina
    Zaffina, Isabella
    Stanga, Lucia
    Arturi, Franco
    LIFE-BASEL, 2022, 12 (08):
  • [6] Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control
    Hsieh, Ming-Chia
    Hsieh, Yi-Ting
    Cho, Tzu-Jung
    Chen, Jung-Fu
    Lin, Shi-Dou
    Chen, Hung-Chun
    Tu, Shih-Te
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2011, 41 (08) : 870 - 878
  • [7] Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review
    Li, Rui
    Xing, Jing
    Mu, Xaojing
    Wang, Hui
    Zhang, Lei
    Zhao, Yu
    Zhang, Yu
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6275 - 6283
  • [8] Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management
    Van Buren, Peter N.
    Toto, Robert
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2011, 18 (01) : 28 - 41
  • [9] Diabetic nephropathy. Current diagnostics and treatment
    Werth, S.
    Lehnert, H.
    Steinhoff, J.
    INTERNIST, 2015, 56 (05): : 513 - 519
  • [10] Diabetic nephropathy. Current diagnostics and treatment
    Werth, S.
    Lehnert, H.
    Steinhoff, J.
    INTERNIST, 2015, 56 (05): : 513 - 519